Clinical Trial Update: A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS) [Phase 3]

View source ↗

Summary

Results from a Phase 3 study evaluating Saizen (somatropin) for safety and efficacy in children with Idiopathic Short Stature have been completed, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Short Stature

Drugs mentioned

• Saizen (somatropin)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Idiopathic Short Stature | Phase 3 | Status: COMPLETED | Results posted: 2016-10-18